• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

METHAMPHETAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • METHAMPHETAMINE chembl:CHEMBL1201201

    Alternate Names:

    METHAMPHETAMINE
    METAMFETAMINE
    J6.362B
    NSC-25115
    D-N-METHYLAMPHETAMINE
    METANFETAMINA
    MÉTAMFÉTAMINE
    DESOXYEPHEDRINE
    (S)-N,ALPHA-DIMETHYLBENZENEETHANAMINE
    D-DEOXYEPHEDRINE
    (ALPHAS)-N,ALPHA-DIMETHYLBENZENEETHANAMINE
    (ΑS)-N,Α-DIMETHYLBENZENEETHANAMINE
    METHAMPHETAMINE, METHYLAMPHETAMINE
    (+)-(S)-P-Α-DIMETHYLPHENETHYLAMINE
    D-DESOXYEPHEDRINE
    METHYL-Β-PHENYLISOPROPYLAMINE
    N-METHYLAMPHETAMINE
    D-PHENYLISOPROPYLMETHYLAMINE
    METHYL-BETA-PHENYLISOPROPYLAMINE
    METAMFETAMINUM
    (+)-(S)-N-ALPHA-DIMETHYLPHENETHYLAMINE
    METHAMPHETAMINUM
    S-METHAMPHETAMINE
    METH
    D-1-PHENYL-2-METHYLAMINOPROPANE
    (S)-N,Α-DIMETHYLBENZENEETHANAMINE
    METHYLAMPHETAMINE
    DEXTROMETHAMPHETAMINE
    chemidplus:537-46-2
    pubchem.compound:10836
    chembl:CHEMBL1201201
    rxcui:6816
    drugbank:01577

    Drug Info:

    Year of Approval approved before 1982
    Drug Class central nervous system stimulants
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications neuroprotectant
    (1 More Sources)

    Publications:

    Gupta S et al., 2011, Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings., J Neurovirol
    Ulus et al., 2000, Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors., Biochem. Pharmacol.
    Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
    Kishimoto M et al., 2008, The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis., Biol Psychiatry
    Borowsky et al., 2001, Trace amines: identification of a family of mammalian G protein-coupled receptors., Proc. Natl. Acad. Sci. U.S.A.
    Grandy, 2007, Trace amine-associated receptor 1-Family archetype or iconoclast?, Pharmacol. Ther.
    Wolinsky et al., 2007, The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia., Genes Brain Behav.
    Xie et al., 2007, Trace amine-associated receptor 1 is a modulator of the dopamine transporter., J. Pharmacol. Exp. Ther.
    Miller et al., 2005, Primate trace amine receptor 1 modulation by the dopamine transporter., J. Pharmacol. Exp. Ther.
    Xie et al., 2007, Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro., J. Pharmacol. Exp. Ther.
    Reese et al., 2007, Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine., J. Pharmacol. Exp. Ther.
    Horton et al., 2011, meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release., J. Pharmacol. Exp. Ther.
    Yasumoto et al., 2009, Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2., Neurosci. Lett.
    Fleckenstein et al., 2007, New insights into the mechanism of action of amphetamines., Annu. Rev. Pharmacol. Toxicol.
    Sulzer et al., 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport., J. Neurosci.
    Chanasong R et al., 2013, Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population., Neurosci Lett
    Jeng et al., 1998, Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons., Psychopharmacology (Berl.)
    Nishio et al., 2002, Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice., Neurosci. Lett.
    Numachi et al., 2007, Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters., Eur. J. Pharmacol.
    Sora et al., 2009, Monoamine transporter as a target molecule for psychostimulants., Int. Rev. Neurobiol.
    Tellez et al., 2010, Autoradiographic study of serotonin transporter during memory formation., Behav. Brain Res.
    Henry et al., 1998, The vesicular monoamine transporter: from chromaffin granule to brain., Neurochem. Int.
    Garcia et al., 2005, Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution., Mol. Pharmacol.
    Escubedo et al., 2009, Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: pharmacological implications., Int. Rev. Neurobiol.
    Fone et al., 2005, Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder., Curr Opin Pharmacol
    Lott et al., 2005, Dopamine transporter gene associated with diminished subjective response to amphetamine., Neuropsychopharmacology
    Madras et al., 2005, The dopamine transporter and attention-deficit/hyperactivity disorder., Biol. Psychiatry
    Kahlig et al., 2005, Amphetamine induces dopamine efflux through a dopamine transporter channel., Proc. Natl. Acad. Sci. U.S.A.
    Gao X et al., 2017, Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese., OMICS
    Iamjan SA et al., 2015, BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence., Pharmacogenomics
    Haerian BS, 2013, BDNF rs6265 polymorphism and drug addiction: a systematic review and meta-analysis., Pharmacogenomics
    Matsuzawa D et al., 2007, Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis., Am J Psychiatry
    Kishi T et al., 2010, Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients., Neuropharmacology
    Kotaka T et al., 2009, G72 gene is associated with susceptibility to methamphetamine psychosis., Prog Neuropsychopharmacol Biol Psychiatry
    Kishi T et al., 2009, A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis., Prog Neuropsychopharmacol Biol Psychiatry
    Ide S et al., 2006, Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms., Pharmacogenomics J
    Zhang W et al., 2020, FAAH levels and its genetic polymorphism association with susceptibility to methamphetamine dependence., Ann Hum Genet
    Sim MS et al., 2013, Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population., Pharmacogenomics
    Ikeda M et al., 2007, Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia., Genes Brain Behav
    Sun Y et al., 2019, Identification of novel risk loci with shared effects on alcoholism, heroin, and methamphetamine dependence., Mol Psychiatry
  • METHAMPHETAMINE   SLC18A1

    Interaction Score: 9.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    9587917 15955613 17209801


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   DAOA

    Interaction Score: 4.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19482054


    Sources:
    PharmGKB

  • METHAMPHETAMINE   PICK1

    Interaction Score: 4.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17606663


    Sources:
    PharmGKB

  • METHAMPHETAMINE   ANKS1B

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31462767


    Sources:
    PharmGKB

  • METHAMPHETAMINE   ARRB2

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17233643


    Sources:
    PharmGKB

  • METHAMPHETAMINE   DTNBP1

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17555717


    Sources:
    PharmGKB

  • METHAMPHETAMINE   SLC18A2

    Interaction Score: 0.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    21177475 19429089 17209801 15955613 7751968


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   TAAR1

    Interaction Score: 0.68

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name low dose intravenous methamphetamine

    PMIDs:
    11459929 17888514 17212650 17234899 15764732 17234900 17218486


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   SLC6A3

    Interaction Score: 0.42

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    15795321 19897077 15661631 15602501 15950014 15764732 17209801 15728379


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   FAAH

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31789429 23556448


    Sources:
    PharmGKB

  • METHAMPHETAMINE   MAOA

    Interaction Score: 0.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    10799660 15955613


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   SLC6A2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    15955613 17209801


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   SLC6A4

    Interaction Score: 0.18

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    17673199 19607959 20226815


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   MAOB

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name low dose intravenous methamphetamine

    PMIDs:
    10799660 15955613


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   BDNF

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28692418 26401760 24279859


    Sources:
    PharmGKB

  • METHAMPHETAMINE   ADRA2B

    Interaction Score: 0.15

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    9551769 15955613


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   ADRA2A

    Interaction Score: 0.13

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    9551769 12453616 15955613


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   GRIN1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23880023


    Sources:
    PharmGKB

  • METHAMPHETAMINE   ADRA2C

    Interaction Score: 0.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    9551769 15955613


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   HTR1A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19747927


    Sources:
    PharmGKB

  • METHAMPHETAMINE   ADRA1B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND TTD

  • METHAMPHETAMINE   DRD3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21491142


    Sources:
    PharmGKB

  • METHAMPHETAMINE   OPRM1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16402083


    Sources:
    PharmGKB

  • METHAMPHETAMINE   ADRA1A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • METHAMPHETAMINE   ESR1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19386276


    Sources:
    PharmGKB

  • METHAMPHETAMINE   DRD2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TEND: METHAMPHETAMINE

    • Version: 01-August-2011

    Alternate Names:
    METHAMPHETAMINE Primary Drug Name

    Drug Info:
    Drug Class central nervous system stimulants
    Year of Approval approved before 1982

    Publications:

  • TdgClinicalTrial: METHAMPHETAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications neuroprotectant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: methamphetamine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Gupta S et al., 2011, Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings., J Neurovirol
    Kishimoto M et al., 2008, The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis., Biol Psychiatry
    Matsuzawa D et al., 2007, Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis., Am J Psychiatry

  • TTD: Methamphetamine

    • Version: 2020.06.01

    Alternate Names:
    D0P6UB TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201201

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21